Current treatment concepts of CML

The elucidation of the triggering molecular mechanism of chronic myeloid leukemia gave rise to the development of imatinib, a tyrosine kinase inhibitor and a prototype of target-oriented drugs. Imatinib led to impressing response and survival rates and now represents the standard therapy of CML. However, a significant proportion of patients do not tolerate or fail to respond to imatinib treatment. Alternative therapies can be offered to those patients. The particular challenge of CML patient management is to recognize an impending imatinib failure by adequate surveillance and to know about therapeutic options to prevent progression of the disease to accelerated phase or blast crisis since these are more difficult to control. Targeted therapy with second-generation tyrosine kinase inhibitors should be used in synopsis with mutational analysis and the patients' history. In this review we present current knowledge of diagnosis, monitoring and therapy strategies of patients with CML.

Medienart:

E-Artikel

Erscheinungsjahr:

2011

Erschienen:

2011

Enthalten in:

Zur Gesamtaufnahme - volume:11

Enthalten in:

Current cancer drug targets - 11(2011), 1 vom: 15. Jan., Seite 31-43

Sprache:

Englisch

Beteiligte Personen:

Leitner, Armin A [VerfasserIn]
Hochhaus, Andreas [VerfasserIn]
Müller, Martin C [VerfasserIn]

Themen:

8A1O1M485B
Antineoplastic Agents
Benzamides
Imatinib Mesylate
Journal Article
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Review

Anmerkungen:

Date Completed 18.05.2011

Date Revised 18.03.2022

published: Print

Citation Status MEDLINE

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM203483073